Warby Parker Inc. WRBY

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
55/100
Moderate

About Warby Parker Inc.

Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada. The company offers eyeglasses and sunglasses; and single-vision, progressive, light-responsive, polarized, blue-light-filtering, tinted, non-prescription, and contact lenses. It also provides accessories, such as cases, pouches, lenses kit with anti-fog spray, travel cases, lenses cloth, anti-fog lens spray, and sun clip-ons through its … Full WRBY analysis →

Competitive advantage assessment

Key strengths

  • Stable Gross Margin Profile Gross margin stability is strong (score 0.74). Low volatility confirms durable consumable pricing.
  • Expanding Operating Margin Operating margin trend is positive (score 0.76). Margin expansion confirms commercial leverage is building.

Key risks

  • Thin Interest Coverage Interest coverage lags peers (score 0.10). Thin coverage limits M&A optionality and raises refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
63

Where WRBY ranks in Medical Instruments & Supplies

Warby Parker Inc. ranks #27 of 62 scored companies in Medical Instruments & Supplies by moat score — the top 44%. The widest moat in the group is Intuitive Surgical, Inc. (ISRG) at 86/100.

Moat scores for companies ranked near WRBY in Medical Instruments & Supplies
# Company Moat score Rating
23 Envista Holdings Corporation NVST 60/100 Moderate
24 BioLife Solutions, Inc. BLFS 60/100 Moderate
25 Hologic, Inc. HOLX 59/100 Moderate
26 Sanara MedTech Inc. SMTI 56/100 Moderate
27 Warby Parker Inc. WRBY 55/100 Moderate
28 KORU Medical Systems, Inc. KRMD 54/100 Moderate
29 AngioDynamics, Inc. ANGO 54/100 Moderate
30 Teleflex Incorporated TFX 54/100 Moderate
31 Repligen Corporation RGEN 53/100 Moderate

See every Medical Devices & Diagnostics company ranked by moat score →

How WRBY scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 63 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 51 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 57 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 64 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 32 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 60 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding WRBY's moat

What is Warby Parker Inc.'s moat score?

Warby Parker Inc. (WRBY) scores 55 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #27 of 62 scored companies in Medical Instruments & Supplies, the top 44%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Medical Instruments & Supplies. Its strongest defense is Commercial Execution (64/100) and its weakest is Capital Structure & Resilience (32/100).

How does Warby Parker Inc. compare with other Medical Instruments & Supplies companies?

Warby Parker Inc. ranks #27 of 62 scored companies in Medical Instruments & Supplies by moat score. The widest moat in Medical Instruments & Supplies is Intuitive Surgical, Inc. (ISRG) at 86/100. The companies ranked closest are Sanara MedTech Inc. (SMTI) at 56 just above it and KORU Medical Systems, Inc. (KRMD) at 54 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Medical Instruments & Supplies. The defenses are then weighted to produce the overall score out of 100.

Why is Warby Parker Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Warby Parker Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and WRBY scores: Pricing Power & Consumable Moat (63), R&D Pipeline & Capital Returns (51), FCF Quality & Cash Conversion (57), Commercial Execution (64), Capital Structure & Resilience (32), Growth Durability (60). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000